vimarsana.com

Erez Chimovits News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Funding steers Cardiovascular Pipeline towards Clinical Entry

Biopharma Corteria, which announced an oversubscribed €65M ($71M) Series A co-led by investment firms OrbiMed (US) and Jeito Capital (EU), will be  using the funding to advance its cardiovascular pipeline into the clinic. Click to read more.

Philip janiakThierry laugelMarie laure ozouxBiopharma corteriaErez chimovitsAndreas wallnoeferPhilip janiaCorteria pharmaceuticalsJeito capitalManaging partnerKurma partnersFountain healthcare partnersV bio venturesInvivo capitalOmnes capital

Corteria Pharmaceuticals Raises €65M in Series A Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

France generalMarie laure ozouxAndreas wallnoeferPhilip janiakErez chimovitsCorteria pharmaceuticalsJeito capitalKurma partnersFountain healthcare partnersV bio venturesInvivo capitalWorsening heartBright heartAcute heart failureWorsening heart failure

ImmPACT Bio Closes $111 Million Series B Financing, Names New Board Chair and New President and CEO, and Updates on Phase 1 Clinical Study in Relapsed/Refractory B-cell Non-Hodgkin s Lymphoma

/PRNewswire/ ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate based chimeric antigen receptor (CAR).

Stanford universityUnited statesSan franciscoCindy xiongRick kendallBristol myers squibbErez chimovitsAntoni ribasJim tananbaumVentyx biosciencesYvonne chenRichard gasterYvonne yamanakaGideon grossUniversity of californiaBaxter global inclusion council

ImmPACT Bio Closes $111 Million Series B Financing, Names New Board Chair and New President and CEO, and Updates on Phase 1 Clinical Study in Relapsed/Refractory B-cell Non-Hodgkin s Lymphoma

/PRNewswire/ ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate based chimeric antigen receptor (CAR).

Stanford universityUnited statesSan franciscoCindy xiongRick kendallBristol myers squibbErez chimovitsAntoni ribasJim tananbaumVentyx biosciencesYvonne chenRichard gasterYvonne yamanakaGideon grossUniversity of californiaBaxter global inclusion council

Cancer therapy co ImmPACT Bio raises $111m

Immpact was formed from a merger between US company Kalthera and a company founded in Israel's FutuRX biotech incubator.

United statesSumant ramachandraErez chimovitsGidi grossIsrael innovation authorityMigal instituteNovartis venture fundBio partnersForesite capitalDecheng capitalSurveyor capital

vimarsana © 2020. All Rights Reserved.